Recombinant Human IL-6 ACF

IL-6 is a pleiotropic cytokine with a wide range of biological activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. IL-6 signals through a cell-surface type I cytokine receptor complex consisting of the ligand-binding IL-6Rα chain (CD126), and the signal transducing component gp130 (CD130). Signal transduction through gp130, the common signal transducer of cytokines related to IL-6, is mediated by the JAK–STAT pathway and the RAS–MAPK pathway. In addition to the membrane-bound receptor, a soluble form of IL-6R (sIL-6R) has been purified from human serum and urine. The sIL-6R / IL-6 complex can stimulate neurite outgrowth and promote survival of neurons, and hence may be important in nerve regeneration through remyelination. IL-6 is relevant to many disease processes such as diabetes, atherosclerosis, depression, Alzheimer’s disease, systemic lupus erythematosus, prostate cancer, and rheumatoid arthritis. There is an interest in developing anti-IL-6 agents as therapy against many of these diseases. Examples of such therapeutic agents include tocilizumab, which has been approved for rheumatoid arthritis and ALD518, described in clinical trials (2-5). Human IL-6 is active on mouse and rat cells. Recombinant Human IL-6 ACF is a non-glycosylated protein containing 184 amino acids, with a molecular weight of 21 kDa.

• Accession Number: P05231
• Synonyms: IFN-β2, B-cell Differentiation Factor, BSF-2, HSF, MGI-2
• Purity: ≥95% determined by reducing and non-reducing SDS-PAGE, UV spectroscopy at 280 nm.
• Bioactivity:  The ED₅₀ is typically less than 1 ng/mL. ED₅₀ is determined by the dose-dependent proliferation of mouse 7TD-1 cells.
• Animal component-free and carrier-free
• Custom packaging available

For research or further manufacturing use only.